Exane Derivatives Neogenomics Inc Transaction History
Exane Derivatives
- $157 Million
- Q2 2022
A detailed history of Exane Derivatives transactions in Neogenomics Inc stock. As of the latest transaction made, Exane Derivatives holds 151 shares of NEO stock, worth $2,388. This represents 0.0% of its overall portfolio holdings.
Number of Shares
151
Previous 2,227
93.22%
Holding current value
$2,388
Previous $27,000
96.3%
% of portfolio
0.0%
Previous 0.01%
Shares
7 transactions
Others Institutions Holding NEO
# of Institutions
276Shares Held
127MCall Options Held
581KPut Options Held
115K-
Black Rock Inc. New York, NY19.7MShares$311 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA14.1MShares$223 Million0.0% of portfolio
-
Brown Advisory Inc8.77MShares$139 Million0.16% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD6.73MShares$106 Million0.06% of portfolio
-
Janus Henderson Group PLC London, X06.62MShares$105 Million0.05% of portfolio
About NEOGENOMICS INC
- Ticker NEO
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 125,796,000
- Market Cap $1.99B
- Description
- NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytoge...